Radioiodine treatment of hyperthyroidism - prognostic factors for outcome

Amit Allahabadia, [No Value] [No Value], Michael Sheppard, Stephen Gough, Jayne Franklyn

Research output: Contribution to journalArticle

181 Citations (Scopus)


There is little consensus regarding the most appropriate dose regimen for radioiodine (131I) in the treatment of hyperthyroidism. We audited 813 consecutive hyperthyroid patients treated with radioiodine to compare the efficacy of 2 fixed-dose regimens used within our center (185 megabequerels, 370 megabequerels) and to explore factors that may predict outcome. Patients were categorized into 3 diagnostic groups: Graves' disease, toxic nodular goiter, and hyperthyroidism of indeterminate etiology. Cure after a single dose of 131I was investigated and defined as euthyroid off all treatment for 6 months or T4 replacement for biochemical hypothyroidism in all groups. As expected, patients given a single dose of 370 megabequerels had a higher cure rate than those given 185 megabequerels, (84.6% vs. 66.6%, P <0.0001) but an increase in hypothyroidism incidence at 1 yr (60.8% vs. 41.3%, P <0.0001). There was no difference in cure rate between the groups with Graves' disease and those with toxic nodular goiter (69.5% vs. 71.4%; P, not significant), but Graves' patients had a higher incidence of hypothyroidism (54.5% vs. 31.7%, P <0.0001). Males had a lower cure rate than females (67.6% vs. 76.7%, P = 0.02), whereas younger patients (
Original languageEnglish
Pages (from-to)3611-3617
Number of pages7
JournalJournal of Clinical Endocrinology and Metabolism
Issue number8
Publication statusPublished - 1 Aug 2001


Dive into the research topics of 'Radioiodine treatment of hyperthyroidism - prognostic factors for outcome'. Together they form a unique fingerprint.

Cite this